Form 4: Halozyme Therapeutics Director Akiko Moni Miyashita Reports Stock and Option Grant

Akiko Moni Miyashita, a director at Halozyme Therapeutics, reports the acquisition of restricted stock units and stock options as part of the company's director compensation program.

Summary

• On May 1, 2025, Akiko Moni Miyashita, a director of Halozyme Therapeutics, received 4,165 shares of common stock as a restricted stock unit (RSU) grant.
• The RSU grant will vest fully on the earlier of May 1, 2026, or the date of the Issuer's next annual meeting of stockholders.
• Miyashita also received an option to purchase 5,750 shares of common stock at an exercise price of $60.03.
• This option grant will also vest fully on the earlier of May 1, 2026, or the date of the Issuer's next annual meeting of stockholders.
• Following these transactions, Miyashita beneficially owns 24,937 shares of common stock and options to purchase 5,750 shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing director compensation. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Industry Context

Director compensation packages often include a mix of cash, stock options, and restricted stock units to incentivize performance and align director interests with shareholder value. This filing reflects a standard practice in publicly traded companies.

Comparison to Industry Standards

• Director compensation packages in the biotechnology industry typically include a mix of cash retainers, equity awards (stock options and restricted stock units), and other benefits.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation strategies for their directors.
• The size of the equity grants is generally determined by the company's market capitalization, financial performance, and the director's role and responsibilities.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning director interests with long-term company performance.
• Employees may see the director compensation as a benchmark for their own potential equity-based rewards.

Key Dates

Keywords

Halozyme Therapeutics, Director Compensation, Akiko Moni Miyashita, Stock Options, Restricted Stock Units, Form 4, Beneficial Ownership